Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer

Cancer Biology and Therapy

Volumn 15, Issue 11, 2014, Pages 1542-1551

  Zheng, Datong ^a,b   Chen, Yanping ^b   Gao, Caijie ^b   Wei, Yongyue ^b   Cao, Guochun ^c   Lu, Nan ^d   Hou, Yayi ^a   Jiang, Xiuqin ^b   Wang, Jianjun ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c JIANGSU CANCER HOSPITAL   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

MDM2; Non small cell lung cancer; P53; Polymorphism; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG TOXICITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADVERSE DRUG REACTION; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHARMACOGENETICS; RISK; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84918550287     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.956599     Document Type: Article

References (36)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/caac.20121
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; http://dx.doi.org/10.1056/NEJMoa011954
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2008; 26:3543-51; PMID:18506025; http://dx.doi.org/10.1200/JCO.2007.15.0375
4. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20:435-9; PMID:8533159; http://dx.doi.org/10.1016/S0968-0004(00)89095-7
5. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-8; PMID:15007088; http://dx.doi.org/10.1200/JCO.2004.07.173
6. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L, Qiao R, Chen H, Wei Q, Wu J, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 2011; 72:238-43; PMID:20943283; http://dx.doi.org/10.1016/j.lungcan.2010.09.001
7. Pan J-H, Han J-X, Wu J-M, Huang H-N, Yu Q-Z, Sheng L-J. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2008; 78:49-55; PMID:18812689; http://dx.doi.org/10.1159/000158454
8. Zhang L, Gao G, Li X, Ren S, Li A, Xu J, Zhang J, Zhou C. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PloS One 2012; 7:e48350; PMID:23118991; http://dx.doi.org/10.1371/journal.pone.0048350
9. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/science.1905840
11. Skaug V, Ryberg D, Arab EHKMO, Stangeland L, Myking AO, Haugen A. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6:1031-7; PMID:10741731
12. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24:6728-41; PMID:15254240; http://dx.doi.org/10.1128/MCB.24.15.6728-6741.2004
13. Lalonde ME, Ouimet M, Lariviere M, Kritikou EA, Sinnett D. Identification of functional DNA variants in the constitutive promoter region of MDM2. Hum Genomics 2012; 6:15; PMID:23244604; http://dx.doi.org/10.1186/1479-7364-6-15
14. Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, Zhou J, Wei Q, Zhang Z. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res: Official J Am Assoc Cancer Res 2008; 14:3633-40; PMID:18519798; http://dx.doi.org/10.1158/1078-0432.CCR-07-5155
15. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602; PMID:15550242; http://dx.doi.org/10.1016/j.cell.2004.11.022
16. Dong J, Ren B, Hu Z, Chen J, Hu L, Dai J, Jin G, Xu L, Shen H. MDM2 SNP309 contributes to nonsmall cell lung cancer survival in Chinese. Mol Carcinogenesis 2011; 50:433-8; PMID:21268124; http://dx.doi.org/10.1002/mc.20727
17. Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010; 10:88; PMID:20219101; http://dx.doi.org/10.1186/1471-2407-10-88
18. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008; 113:799-807; PMID:18618574; http://dx.doi.org/10.1002/cncr.23668
19. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28:2262-7; PMID:17827408; http://dx.doi.org/10.1093/carcin/bgm191
20. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. HumMutat 2006; 27:110-7; PMID:16287156; http://dx.doi.org/10.1002/humu.20277
21. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer J Int Cancer 2006; 119:718-21; PMID:16496380; http://dx.doi.org/10.1002/ijc.21872
22. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genetics 2003; 33:357-65; PMID:12567188; http://dx.doi.org/10.1038/ng1093
23. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Du-rbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-73; PMID:20981092; http://dx.doi.org/10.1038/nature09534
24. Nancy P, Sakkaraiappan R, Vinay KJ. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer 2004; 6:79-82; PMID:15476592; http://dx.doi.org/10.1016/S1525-7304(11)70205-4
25. Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010; 213:140-5; PMID:20189873; http://dx.doi.org/10.1016/j.ijheh.2010.01.004
26. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374(9699):1432-40; PMID:19767093; http://dx.doi.org/10.1016/S0140-6736(09)61497-5
27. Li CH, Liu MY, Liu W, Li DD, Cai L. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2014; 15 (2): 731-6; PMID:24568487; http://dx.doi.org/10.7314/APJCP.2014.15.2.731
28. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006; 27:2028-33; PMID:16675470; http://dx.doi.org/10.1093/carcin/bgl047
29. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer J Int Cancer 2006; 118:1275-8; PMID:16152608; http://dx.doi.org/10.1002/ijc.21463
30. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005; 280:26776-87; PMID:15908423; http://dx.doi.org/10.1074/jbc.M505203200
31. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics 2010; 10: 54-61; PMID:19786980
32. Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat 2012; 132: 947-53; PMID:21706156; http://dx.doi.org/10.1007/s10549-011-1637-5
33. Wang X, Wang YZ, Ma KW, Chen X, Li W. MDM2 rs2279744 and TP53 rs1042522 Polymorphisms Associated with Etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients. Oncol Res Treat 2014; 37(4): 176-80; PMID:24732641; http://dx. doi.org/10.1159/000360785
34. Xu B, Mi Y-Y, Min Z-C, Cheng G, Tong N, Tao J, Li P-C, Wang M-L, Tang J-L, Zhang Z-D. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol Ints 2010; 85:401-5; PMID:20664183; http://dx.doi.org/10.1159/000315991
35. Yong Y, Lin H. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15:97-8; PMID:15740637; http://dx.doi.org/10.1038/sj.cr.7290272
36. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-9; PMID:14574645; http://dx.doi.org/10.1086/379378